H3N2 infection - Pipeline Insight, 2024

H3N2 infection - Pipeline Insight, 2024

DelveInsight’s, “H3N2 infection- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

H3N2 infection: Understanding

H3N2 infection: Overview

Influenza A virus subtype H3N2 (A/H3N2) is a subtype of viruses that causes influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 viruses have circulated in humans since their pandemic emergence in 1968 and are generally associated with uncomplicated disease in young healthy adults. However, epidemics caused by H3N2 viruses have been more severe than those caused by seasonal H1N1 or influenza B viruses. Influenza viruses that normally circulate in pigs are called “variant” viruses when they are found in people. Influenza a H3N2 variant viruses (also known as “H3N2v” viruses) with the matrix (M) gene from the 2009 H1N1 pandemic virus were first detected in people in July 2011. H3N2 virus infections boost non-neutralizing H3N2 antibodies in middle-aged individuals, potentially leaving many of them in a perpetual state of 3c2. Because the influenza virus changes so frequently it is hard to identify and treat and even harder to develop a vaccine months in advance of flu season. Symptoms are similar no matter what strain of influenza is circulating each year. Treatment may include antiviral medications if diagnosed early; otherwise, rest, lots of fluids, and OTC medications can help relieve symptoms.

Diagnosis of H3N2 virus infection includes clinical evaluation and laboratory tests. Special laboratory tests are performed to confirm the diagnosis and distinguish it from other respiratory diseases. Such as, Rapid Influenza Diagnostic Test (RIDT) This diagnostic test is used for initial screening and Image provides rapid results within minutes using a nose or throat swab. RIDT is convenient and provides rapid results. Viral culture allows further analysis and characterization of specific strains, which can be helpful for control purposes and monitoring the evolution of the virus. PCR (Polymerase chain reaction) is a molecular technique that amplifies and detects viral genetic material with high sensitivity and specificity. It is particularly useful for confirming this diagnosis when fast and accurate results are required. Serological tests detect the presence of antibodies produced by the immune system in response to infection with the H3N2 virus. These tests may be used for epidemiological investigations, surveillance, and research.

Antiviral drugs are prescribed to treat the flu for people at high risk of complications or who have a severe form of the flu. Anti-flu drugs can only treat the flu and no other viral infections. In addition, it does not replace the annual vaccine; using the two together can help reduce the risk of complications. Examples are Oseltamivir phosphate (Tamiflu), Zanamivir (Relenza), Peramivir (Rapivab), and Baloxavir Marboxil (Zofluza).

""H3N2 infection- Pipeline Insight, 2024"" report by Delve Insight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the H3N2 infection pipeline landscape is provided which includes the disease overview and H3N2 infection treatment guidelines. The assessment part of the report embraces, in depth H3N2 infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, H3N2 infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence H3N2 infection R&D. The therapies under development are focused on novel approaches to treat/improve H3N2 infection.

H3N2 infection Emerging Drugs Chapters

This segment of the H3N2 infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

H3N2 infection Emerging Drugs

mRNA-1083: Moderna Therapeutics

mRNA-1083 is under development for the prevention of influenza virus infection caused by influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria strains and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in 18 to 79 years of age group. It is a combination vaccine of mRNA-1283, which encodes Receptor Binding Doman (RBD) and N-Terminal Domain (NTD) of the spike protein and mRNA-1010, which encodes hemagglutinin (HA) glycoproteins of influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria-lineages. It is administered through intramuscular route in the form of sterile liquid for injection. Currently, the drug is in Phase III stage of its clinical trial for the treatment H3N2 infection.

CD-388: Cidara therapeutics

CD-388 is under development of the treatment and prevention of influenza virus A, seasonal influenza, pandemic influenza and influenza virus B infections. The drug candidate is a second generation, anti-viral Fc conjugate (AVC). It comprises of two moieties attached through a chemical linker. One is a targeting moiety (TM) that recognizes cell surface target and another is an effector moiety (EM) that is recognized by the immune system. It is administered through intramuscular and subcutaneous route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of H3N2 infection.

PF-07845104: Pfizer

PF-07845104 is a prophylactic saRNA Vaccine developed by Pfizer. Its therapeutics area include infectious respiratory diseases. Currently, the drug is in phase I stage of its clinical trial for the treatment of H3N2 infection.

Further product details are provided in the report……..

H3N2 infection: Therapeutic Assessment

This segment of the report provides insights about the different H3N2 infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in H3N2 infection

There are approx. 15+ key companies which are developing the therapies for H3N2 infection. The companies which have their H3N2 infection drug candidates in the most advanced stage, i.e. Phase III include, Moderna Therapeutics.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

H3N2 infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

H3N2 infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses H3N2 infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging H3N2 infection drugs.

H3N2 infection Report Insights

H3N2 infection Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

H3N2 infection Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing H3N2 infection drugs?

How many H3N2 infection drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of H3N2 infection?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the H3N2 infection therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for H3N2 infection and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis Vaccines

PDS Biotechnology Corporation

Sanofi

Moderna Therapeutics

Pfizer

Cidara therapeutics

GRDG SCIENECES

FluGen Inc.

Barinthus Biotherapeutics

Key Products

NanoFlu

PDS0202

MRT-5400

mRNA 1083

PF-07845104

CD 388

Equivir

H3N2 M2SR influenza vaccine

MVA-NP+M1